A 35-year-old obese diabetic man presented with recurrent primary hyperparathyroidism during a threeyear outpatient follow-up. He was clinically diagnosed with multiple endocrine neoplasia type 1 (MEN1) due to the presence of a pituitary adenoma and multiple glucagonomas. The glucagonomas may have affected his glycemic control. However, he did not demonstrate weight loss, suggesting that the patient's obesity could have obscured the early diagnosis of a glucagonoma. Genetic testing revealed a novel missense mutation at codon 561 in exon 10, resulting in an amino acid substitution from methionine to arginine (M561R) in the MEN1 gene. This mutation appeared to be responsible for the MEN1 pathogenicity.
Introduction
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder which appears to be associated with heterozygous germinal mutations of the MEN1 tumor suppressor gene. MEN1 is clinically diagnosed by confirming a neoplastic disease in at least two of the commonly affected organs: the parathyroid gland, endocrine pancreas, and anterior pituitary gland. However, its clinical presentation varies among individuals, and less commonly affected lesions can include adenomas of the adrenal glands, neuroendocrine tumors, and lipomas (1, 2) .
The MEN1 gene comprises 10 exons and exon 2 through 10 encodes the 610-amino acid protein menin. Although the biological function of menin still remains poorly understood, it has been suggested that it suppresses tumorigenesis. Tumorigenesis in the MEN1 patients is commonly explained by Knudson's two-hit theory with a loss of heterozygosity in the MEN1 gene (3, 4) . Therefore, DNA testing for MEN1 is an established and useful tool for the diagnosis of MEN1 (1, 5, 6) . As previously reported, 20-30% of the germline MEN1 mutations are missense mutations (2, 5) . However, the confirmation of the pathogenicity of these mutations remains very challenging in clinical settings (7) . Therefore, the accumulation of pathogenic missense MEN1 gene mutations should prove valuable for clinicians. Moreover, a glucagonoma is a rare pancreatic endocrine tumor, even in MEN1 (1, 2) , with well-known clinical features including secondary diabetes mellitus and weight loss (8, 9) .
We herein report a MEN1 patient who presented with glucagonomas and was revealed to possess a novel germline missense mutation of the MEN1 gene. Additionally, this case demonstrates the possibility of obesity obscuring the early diagnosis of a glucagonoma, given that the patient presented with diabetes mellitus and obesity. 
Case Report
A 32-year-old man was referred to our hospital for the evaluation and treatment of diabetes mellitus. He developed primary hyperparathyroidism at 31 years of age, for which he underwent parathyroidectomy of the bilateral inferior glands, and pathological findings of which were consistent with parathyroid hyperplasia (Fig. 1a ). His father had diabetes mellitus and a giant lipoma on the shoulder and died from pancreatic tumor in his fifties. The other family history was unremarkable. The height of the patient was 176 cm, and he weighed 103 kg. His body mass index (BMI) was 33.3 kg/m 2 . Laboratory testing revealed an elevated HbA1c level (6.9%; normal range, 4.7-6.2%), fasting plasma glucose (177 mg/dL; normal range, 60-110 mg/dL), and serum C-peptide (10.4 ng/mL; normal range, 0.7-2.5 ng/mL). Anti-GAD antibody testing was negative (<0.3 U/mL; normal range, 0-1.4 U/mL). The patient was thus diagnosed with type 2 diabetes mellitus and obesity. He had been previously treated with metformin (1,000 mg/day) and sitagliptin (50 mg/day) in addition to diet and exercise therapy. The levels of HbA1c following treatment were less than 6.5%.
At a regular outpatient visit (age: 35 years), the patient presented with a recurrence of primary hyperparathyroidism. Laboratory testing revealed hypercalcemia (corrected serum calcium level, 11.6 mg/dL; normal range, 8.2-10 mg/dL) with an elevated serum intact parathyroid hormone (PTH) level [237 pg/mL; normal range, 10-65 pg/mL; measured using an electrochemiluminescence immunoassay (Mitsubishi Chemicals, Tokyo, Japan)]. A significant uptake in the parathyroid gland located in the right inferior thyroid was demonstrated by 99m technetium-sestamibi ( 99m Tc-MIBI) scintigraphy, and additional parathyroidectomy of the gland was performed. On the following day after surgery, the levels of corrected serum calcium (9.9 mg/dL) and intact PTH (5 pg/ mL) immediately improved. A pathological examination of the resected parathyroid was consistent with multiglandular parathyroid hyperplasia ( Fig. 1b) .
We subsequently performed clinical screening for other endocrine organs due to the high suspicion of MEN1. Consequently, a pituitary mass, suggesting a microadenoma, was detected by dynamic contrast-enhanced magnetic resonance imaging (MRI) ( Fig. 2a ). Furthermore, abdominal computed tomography (CT) and the MRI scans revealed a left adrenocortical tumor (Fig. 2b) . The abdominal dynamic CT scans also demonstrated a cystic tumor with early rim enhancement in the head of pancreas and another multilocular cystic tumor in the distal part of the pancreas (Fig. 3 ). Both tumors demonstrated a high-signal intensity on the T2weighted MR images. Although laboratory testing indicated that the pituitary and adrenal tumors were non-functioning (Table) , the fasting blood samples showed elevated levels of plasma glucagon (800 pg/mL; normal range, 70-174 pg/mL, measured by a double antibody radioimmunoassay, SRL, Tokyo, Japan), serum gastrin (380 pg/mL; normal range, 0-200 pg/mL, measured by a radioimmunoassay with the polyethylene glycol technique, SRL), and a decreased total plasma amino acid concentration (1,787.8 nmoL/mL; normal range, 2,068.2-3,510.3 nmoL/mL, measured by liquid chromatography-mass spectrometry, SRL). A gastrin stimulation test after calcium infusion was found to be negative. Therefore, the clinical diagnosis of a glucagonoma was established. Twenty-three weeks after the second parathyroidectomy, enucleation of the tumor in the head of the pancreas and distal pancreatectomy were performed. However, the patient did not demonstrate any weight loss, and the glycemic control was gradually lost during the course. Before undergoing pancreatic surgery, the patient's body weight was 106 kg and the HbA1c level was 7.6%. A pathological examination revealed numerous small tumors, measuring less than 5 mm in diameter, in the distal pancreas in addition to the two tumors detected preoperatively. Concerning the tumor in the head of pancreas ( Fig. 4a, b) , immunochemical studies showed positive staining for chromogranin A (Fig. 4c ) and synaptophysin and diffuse positive staining for glucagon ( Fig. 4d ). Concerning the tumor in the distal pancreas ( Fig. 4a, e ), immunochemical studies additionally demonstrated positive staining for chromogranin A (Fig. 4f) and synaptophysin and spotty positive staining for glucagon ( Fig. 4g ). Therefore, both tumors were pathologically confirmed to be glucagonomas. The Ki-67 proliferative indices of these tumors were 3%. No nodal or distal metastases were observed. The patient's pathological staging was considered to be T3N0M0 (stage IIb) and T2N0M0 (stage Ib), according to the AJCC/UICC and European Neuroendocrine Tumor Society TNM staging system, respectively. One week after surgery, the plasma glucagon concentration decreased (183 pg/mL). In addition, the glycemic control improved followed by metformin (500 mg/day) treatment and the HbA 1c level decreased to 6.6% 14 weeks after the surgery. Exon 2 through 10 of the MEN1 gene were amplified by polymerase chain reaction, using genomic DNA extracted from leukocytes, after obtaining written informed consent from the patient. A heterozygous T to G change was identified at codon 561 in exon 10 (Fig. 5a ), which resulted in the replacement of methionine to arginine (M561R). As this mutation has not yet been reported, the pathogenicity of this 
(a)
A G G (b) mutation was analyzed by an in silico analysis. The Polymorphism Phenotyping version 2 (PolyPhen-2) software program predicted the mutation to be potentially damaging, and the Scale-Invariant Feature Transform (SIFT) software program predicted it to be damaging. Moreover, the tissue loss of heterozygosity (LOH) in the tumor of the pancreatic head was shown (Fig. 5b ). Further genetic testing in the patient's family indicated that his 33-year-old sister had the same M561R mutation, although his 61-year-old mother and 31year-old sister did not. However, at the time of this report, contrary to our recommendation, the sister with the mutation had not yet been examined for any biochemical abnormalities. The genetic analyses of MEN1 were approved by the Institutional Review Board of the Osaka Red Cross Hospital and the National Hospital Organization Kyoto Medical Center. Moreover, genetic testing and counseling was pursued only after obtaining written informed consent from each family member individually.
Discussion
The clinical diagnosis of MEN1 depends on the identification of neoplastic disease in at least two of the commonly affected organs: the parathyroid gland, endocrine pancreas, and anterior pituitary (1, 2) . As previously reported, primary hyperparathyroidism, gastroenteropancreatic neuroendocrine tumors (GEPNETs), and pituitary tumors occur in 95%, 40-70%, and 30-40% of cases, respectively. In addition, some MEN1 patients may develop adrenal cortical tumors (40%) and lipomas (30%) (1, 2) . In the present case, the diagnosis of MEN1 was demonstrated by early-onset primary hyperparathyroidism with multiple affected glands, pancreatic neuroendocrine tumors, and pituitary and adrenal tumors, suggesting adenomas. The history of pancreatic tumors and lipomas in the patient's father supported the diagnosis, al-though no detailed clinical information was available.
As mentioned in the case presentation, the present patient received the first parathyroidectomy of both inferior glands at another hospital. However, 99m Tc-MIBI scintigraphy and the second surgery performed in our hospital demonstrated an affected parathyroid gland located in the right inferior thyroid. This indicates that the patient possibly had five parathyroid glands in total. Moreover, in general, total parathyroidectomy with autotransplantation or subtotal parathyroidectomy should be recommended in MEN1 cases (1) . However, in the present case, the second parathyroidectomy, which was not total or subtotal parathyroidectomy, was performed before the definitive diagnosis of MEN1 since the patient requested early surgery of the affected gland due to recurrent urinary lithiasis, although we explained the possible necessity of total parathyroidectomy. Therefore, in the present case, a total parathyroidectomy with autotransplantation is planned for the near future.
MEN1 germline mutation testing is very useful for the diagnosis of MEN1 and should be offered to index patients with MEN1 and their relatives (1) (2) (3) . In fact, heterozygous germline mutations of the MEN1 gene have been identified in approximately 90% of all MEN1 patients. In the present study, a direct sequencing analysis revealed a missense mutation at codon 561 in exon 10 which resulted in an amino acid substitution from methionine to arginine (M561R) of the MEN1 gene. To the best of our knowledge, this mutation has not been previously reported (10) or registered in The Human Gene Mutation Database (HGMD ). Generally, when a missense mutation is identified in an affected subject, it is necessary to evaluate its pathogenicity (7) . The confirmation of the pathogenicity of these mutations remains very challenging in the clinical setting, although various methods to analyze their pathogenicity have been reported (7) . LOH in the pancreatic neuroendocrine tumor provided strong evidence that the mutation was responsible for tumorigenesis in the present case (11) . Moreover, in silico analysis programs have emerged as reasonable tools for the evaluation of the pathogenicity of missense mutations (12, 13) . Evidence of their validity has been previously reported for MEN1 gene mutations (14, 15) . In the case of the M561R mutation, the results of PolyPhen-2 and SIFT support the damaged function of menin. In addition, the pathogenicity of the mutation was supported by the evolutionary conservativeness and molecular functions of codon 561. The methionine was shown to be a conserved amino acid among various vertebrate species, such as mouse, rat, zebrafish, and human (5, 16) . It also comprises the accessory nuclear localization signal for menin, which plays an essential role in controlling gene transcription and nuclear translocation through binding to the proteins such as Smad3, check point suppressor 1, and activator of S-phase kinase (5, 16) . Thus, we concluded that the M561R mutation of the MEN1 gene is a novel missense mutation responsible for MEN1.
There is often a delay in the diagnosis of MEN1 (17), as was the case in the present patient, in whom the interval between the diagnosis of early-onset primary hyperparathyroidism with multiglandular hyperplasia and that of MEN1 was four years. The characteristic symptoms of MEN1 should not be overlooked and its diagnosis should always be considered in the differential diagnosis. Similar to MEN1, there is often a delayed diagnosis of GEPNETs (15) . A glucagonoma is a rare GEPNET, seen in only 3-13% of all MEN1 cases (1.2) and 1-5% of all pancreatic endocrine tumors (9, 18, 19) . Furthermore, a glucagonoma is recognized as a very rare cause of secondary diabetes mellitus, in which glucose intolerance develops through the stimulation of liver glyconeogenesis and insulin secretion. As previously reported, 88.4% of the glucagonoma patients showed glucose intolerance (8, 9) . In the present case, a glucagonoma could have affected the glucose metabolism due to the relatively early onset of diabetes mellitus, which demonstrated a gradually lost glycemic control within two years and a rapidly improved glycemic control after pancreatectomy. In addition, weight loss is also a wellknown clinical feature of a glucagonoma, with a prevalence rate of 31.3-76.6% and a mean BMI (at diagnosis) of 19.7 kg/m 2 (8, 9) . The hypersecretion of glucagon causes lipolysis and proteolysis, leading to weight loss (9) . Conversely, liver glyconeogenesis and insulin hypersecretion, which may suppress lipolysis, can often be observed in patients with type 2 diabetes associated with obesity, one of the most common chronic diseases (19) . Moreover, obesity may present hypothalamic glucagon resistance, which could offset the central suppression of liver glyconeogenesis (20) . Therefore, obesity itself may possibly suppress lipolysis even in an inappropriately excess of glucagon. The present patient was obese and did not exhibit weight loss during the clinical course; in addition, he showed signs of hyperinsulinemia at the first visit to our hospital (fasting plasma glucose: 177 mg/dL: serum C-peptide: 10.4 ng/mL). This most likely contributed to the late diagnosis of the glucagonoma. However, when it was eventually diagnosed, the measurement of the plasma glucagon level was very useful in making the diagnosis, as previously reported (8, 9) . Therefore, the possibility of a glucagonoma, even in obese diabetic patients without weight loss, should be taken into consideration since obesity may obscure the glucagonoma-induced symptoms through glucagon resistance.
In summary, we herein reported a case of MEN1 with a novel missense mutation M561R of the MEN1 gene, which appeared to be responsible for MEN1. The present case demonstrated the presence of glucagonomas in a patient with diabetes mellitus and obesity. Therefore, the measurement of the plasma glucagon level should be considered in the differential diagnosis of secondary diabetes mellitus even in obese patients without weight loss.
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